NOVEL FULVESTRANT FORMULATION
Total Payments
$1.9M
Transactions
30
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $1.9M | 30 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.9M | 30 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF FULVESTRANT AFTER IM ADMINISTRATION | EAGLE PHARMACEUTICALS, INC. | $1.9M | 0 |
Top Doctors Receiving Payments for NOVEL FULVESTRANT FORMULATION
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Miami, FL | $1.9M | 30 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.9M
- Total Doctors 0
- Transactions 30
About NOVEL FULVESTRANT FORMULATION
NOVEL FULVESTRANT FORMULATION is a drug associated with $1.9M in payments to 0 healthcare providers, recorded across 30 transactions in the CMS Open Payments database. The primary manufacturer is EAGLE PHARMACEUTICALS, INC..
Payment data is available from 2020 to 2020. In 2020, $1.9M was paid across 30 transactions to 0 doctors.
The most common payment nature for NOVEL FULVESTRANT FORMULATION is "Unspecified" ($1.9M, 100.0% of total).
NOVEL FULVESTRANT FORMULATION is associated with 1 research study, including "STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF FULVESTRANT AFTER IM ADMINISTRATION" ($1.9M).